Federal Register / Vol. 69, No. 223 / Friday, November 19, 2004 / Notices 67737

Controlling the Assault of Non-Solicited 

Pornography and Marketing Act of 2003 

(CG Docket No. 04–53). 

Number of Petitions Filed: 1.

Marlene H. Dortch, 

Secretary.

[FR Doc. 04–25743 Filed 11–18–04; 8:45 am] 

BILLING CODE 6712–01–M

FEDERAL RESERVE SYSTEM

Change in Bank Control Notices; 

Acquisition of Shares of Bank or Bank 

Holding Companies

The notificants listed below have 

applied under the Change in Bank 

Control Act (12 U.S.C. 1817(j)) and 

§ 225.41 of the Board’s Regulation Y (12 

CFR 225.41) to acquire a bank or bank 

holding company. The factors that are 

considered in acting on the notices are 

set forth in paragraph 7 of the Act (12 

U.S.C. 1817(j)(7)).

The notices are available for 

immediate inspection at the Federal 

Reserve Bank indicated. The notices 

also will be available for inspection at 

the office of the Board of Governors. 

Interested persons may express their 

views in writing to the Reserve Bank 

indicated for that notice or to the offices 

of the Board of Governors. Comments 

must be received not later than 

December 3, 2004.

A. Federal Reserve Bank of Kansas 

City (Donna J. Ward, Assistant Vice 

President) 925 Grand Avenue, Kansas 

City, Missouri 64198-0001:

1. Embry W. Williams, Jr., Amarillo, 

Texas; to acquire additional voting 

shares of Union BancShares, Inc., 

Clayton, New Mexico, and thereby 

indirectly acquire additional voting 

shares of First National Bank of New 

Mexico, Clayton, New Mexico.

Board of Governors of the Federal Reserve 

System, November 15, 2004.

Robert deV. Frierson,

Deputy Secretary of the Board.

[FR Doc. 04–25689 Filed 11–18–04; 8:45 am]

BILLING CODE 6210–01–S

FEDERAL RESERVE SYSTEM

Notice of Proposals to Engage in 

Permissible Nonbanking Activities or 

to Acquire Companies that are 

Engaged in Permissible Nonbanking 

Activities

The companies listed in this notice 

have given notice under section 4 of the 

Bank Holding Company Act (12 U.S.C. 

1843) (BHC Act) and Regulation Y (12 

CFR Part 225) to engage de novo, or to 

acquire or control voting securities or 

assets of a company, including the 

companies listed below, that engages 

either directly or through a subsidiary or 

other company, in a nonbanking activity 

that is listed in § 225.28 of Regulation Y 

(12 CFR 225.28) or that the Board has 

determined by Order to be closely 

related to banking and permissible for 

bank holding companies. Unless 

otherwise noted, these activities will be 

conducted throughout the United States.

Each notice is available for inspection 

at the Federal Reserve Bank indicated. 

The notice also will be available for 

inspection at the offices of the Board of 

Governors. Interested persons may 

express their views in writing on the 

question whether the proposal complies 

with the standards of section 4 of the 

BHC Act. Additional information on all 

bank holding companies may be 

obtained from the National Information 

Center website at www.ffiec.gov/nic/.

Unless otherwise noted, comments 

regarding the applications must be 

received at the Reserve Bank indicated 

or the offices of the Board of Governors 

not later than December 3, 2004.

A. Federal Reserve Bank of Atlanta

(Sue Costello, Vice President) 1000 

Peachtree Street, N.E., Atlanta, Georgia 

30303:

1. DBT Holding Company, Vidalia, 

Georgia; to engage de novo through its 

subsidiary, DBW Technologies, LLC, 

Atlanta, Georgia, in data processing 

activities, pursuant to section 

225.28(b)(14)(i) of Regulation Y.

Board of Governors of the Federal Reserve 

System, November 15, 2004.

Robert deV. Frierson,

Deputy Secretary of the Board.

[FR Doc. 04–25690 Filed 11–18–04; 8:45 am]

BILLING CODE 6210–01–S

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Office of the Secretary 

Findings of Scientific Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

SUMMARY: Notice is hereby given that 

the Office of Research Integrity (ORI) 

and the Acting Assistant Secretary for 

Health have taken final action in the 

following case: 

Ali Sultan, M.D., Ph.D., Harvard 

School of Public Health: On October 19, 

2004, the U.S. Public Health Service 

(PHS) entered into a Voluntary 

Exclusion Agreement with the President 

and Fellows of Harvard College 

(Harvard) and Ali Sultan, M.D., Ph.D., 

former Assistant Professor of 

Immunology and Infectious Diseases at 

the Harvard School of Public Health 

(HSPH). Based on HSPH’s inquiry 

report, the respondent’s admission, and 

additional analysis conducted by ORI in 

its oversight review, PHS found that Dr. 

Sultan engaged in scientific misconduct 

in research funded by National Institute 

of Allergy and Infectious Diseases 

(NIAID), National Institutes of Health 

(NIH), grant 1 P01 AI060332–01, 

‘‘Chemical genetics and malaria drug 

development,’’ Subproject 2, ‘‘Screening 

of target-rich environment.’’

Specifically, PHS and Harvard found 

that: 

• Dr. Ali Sultan plagiarized text, 

plagiarized three figures showing results 

of an immunofluorescence assay, a 

phosphorimage, and northern blot 

analysis (Figures 3, 4, and 5, 

respectively), and falsified the data as 

results of experiments on Plasmodium 

bergheii, instead of P. falciparum as 

reported in a subproject of the PHS 

grant application 1 P01 AI060332–01, 

‘‘Chemical genetics and malaria drug 

development.’’

• Dr. Ali Sultan fabricated portions of 

an e-mail from his postdoctoral student 

that he presented to the HSPH inquiry 

committee purportedly to falsely 

implicate the student in the submission 

of the plagiarized materials for the grant 

application. 

The Voluntary Exclusion Agreement 

states that for a period of three (3) years, 

beginning on October 19, 2004: 

(1) Dr. Sultan agreed to exclude 

himself from any contracting or 

subcontracting with any agency of the 

United States Government and from 

eligibility or involvement in 

nonprocurement programs of the United 

States Government as defined in the 

debarment regulations at 45 CFR part 

76; and 

(2) Dr. Sultan agreed to exclude 

himself from serving in any advisory 

capacity to PHS including but not 

limited to service on any PHS advisory 

committee, board, and/or peer review 

committee, or as a consultant.

FOR FURTHER INFORMATION CONTACT:

Director, Division of Investigative 

Oversight, Office of Research Integrity, 

1101 Wootton Parkway, Suite 750, 

Rockville, MD 20852, (301) 443–5330.

Dated: November 10, 2004. 

Chris B. Pascal, 

Director, Office of Research Integrity.

[FR Doc. 04–25648 Filed 11–18–04; 8:45 am] 

BILLING CODE 4150–31–P